Suns complete buyout of Bradley Beal, guard securing contract with Clippers
The Arizona Republic confirmed the deal with Beal's agent, Mark Bartelstein of Priority Sports, as the second year is a player option.
ESPN's Shams Charania first reported the deal.
Beal averaged 17.6 points in two seasons with the Suns, who acquired him in a trade with Washington in the summer of 2023 in a deal involving Chris Paul.
Phoenix was deemed a championship contender with Devin Booker, Kevin Durant and Beal, but fell way short of those expectations, failing to make the playoffs last season.
Have opinions about the current state of the Suns? Reach Suns Insider Duane Rankin at dmrankin@gannett.com or contact him at 480-810-5518. Follow him on X, formerly Twitter, at @DuaneRankin.
Support local journalism: Subscribe to azcentral.com today.
This article originally appeared on Arizona Republic: Phoenix Suns finish buyout of Bradley Beal, who plans to join Clippers
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
North American Financial 15 Split Corp. Monthly Dividend Declaration for Class A & Preferred Share
TORONTO, July 18, 2025 (GLOBE NEWSWIRE) -- North American Financial 15 Split Corp. (The "Company") declares its regular monthly distribution of $0.11335 for each Class A share ($1.3602 annualized) and $0.07292 for each Preferred share ($0.875 annually). Distributions are payable August 8, 2025 to shareholders on record as at July 31, 2025. Since inception Class A shareholders have received a total of $18.08 per share and Preferred shareholders have received a total of $12.20 per share inclusive of this distribution, for a combined total of $30.28. The Company invests in a high quality portfolio consisting of 15 financial services companies made up of Canadian and U.S. issuers as follows: Bank of Montreal, The Bank of Nova Scotia, Canadian Imperial Bank of Commerce, Royal Bank of Canada, Toronto-Dominion Bank, National Bank of Canada, Manulife Financial Corporation, Sun Life Financial, Great-West Lifeco, CI Financial Corp, Bank of America, Citigroup Inc., Goldman Sachs Group, JP Morgan Chase & Co. and Wells Fargo & Co. Distribution Details Class A Share (FFN) $0.11335 Preferred Share ( $0.07292 Record Date: July 31, 2025 Payable Date: August 8, 2025 Investor Relations: 1-877-478-2372 Local: 416-304-4443 info@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Hepatitis Testing Market Size to Reach USD 5.75 Billion by 2032 Driven by Rising Prevalence, Early Detection Demand, and Technological Advancements
U.S. Hepatitis Testing Market to Hit USD 1.94 Billion by 2032, Robust Infrastructure and Growing Demand for Early Detection Tools Fuels Growth. Austin, July 18, 2025 (GLOBE NEWSWIRE) -- Hepatitis Testing Market Size & Growth Analysis: According to SNS Insider, the global Hepatitis Testing Market was valued at USD 3.53 billion in 2023 and is projected to reach USD 5.75 billion by 2032, growing at a CAGR of 5.62% during the forecast period 2024-2032. The global hepatitis testing market is growing significantly due to the increasing incidence of hepatitis B and C infections, growing awareness around early diagnosis, and government-driven screening programs. Further, technological improvements in serological and molecular testing have enhanced test sensitivity and turnaround times, contributing to market Your Free Sample Copy of the Hepatitis Testing Market Report Today: The U.S. accounted for a substantial portion of the global market, valued at USD 1.22 billion in 2023, and is projected to reach USD 1.94 billion by 2032. This dominance is attributed to the presence of major diagnostic players, high healthcare spending, and a robust testing infrastructure across hospitals and diagnostic laboratories. Market Overview The hepatitis testing market is growing owing to the increase in demand for accurate diagnostic products, especially with the increase in the number of global hepatitis infections. Public health organizations such as the WHO and CDC are promoting mass screening and early diagnosis policies, extending the scope and frequency of hepatitis testing across the globe. Multitarget detection has changed the testing landscape with respect to hepatitis viruses in recent years, especially due to advancements in immunoassay and PCR-based diagnostics that now allow simultaneous testing. Furthermore, growing trend towards integrated healthcare systems and government initiatives for reimbursement policies will encourage the adoption of diagnosis testing kits. Developed regions such as North America and Europe with well-established laboratory networks and insurance policies conducive to mass screening. At the same time, low and middle-income countries are fast catching up because of increased awareness and international healthcare partnerships. The rising interest in point-of-care testing and home-use testing products will also drive long-term market growth in the next ten years. Major Players Analysis Listed in this Report are: Abbott Laboratories (Architect Anti-HCV, Alinity HCV) Analytik Jena (AdiSelect HCV, AdiSelect HCV Real-Time PCR Kit) Autobio Diagnostics (HCV Antibody Test Kit, HEV Antibody Test Kit Bio-Mérieux (VIDAS Anti-HCV, VIDAS HEV) Danaher Corporation (Cepheid Xpert HCV, LumiraDx HCV Test) DiaSorin (LIAISON HCV, LIAISON HCV) Grifols SA (Procleix HCV Assay, Procleix HEV Assay) Hologic Inc. (Aptima HCV Assay, Aptima HEV Assay) MedMira Inc. (Reveal HCV Test, Reveal HEV Test) Ortho-Clinical Diagnostics (Vitros Anti-HCV Test, Vitros HEV Test) Qualpro Diagnostics (HCV Rapid Test, HEV Rapid Test) Roche Molecular Diagnostics (Cobas HCV Test, Cobas HEV Test Siemens Healthcare (ADVIA Centaur HCV, Dimension Vista HEV) Sysmex Corporation (Sysmex HCV Test, Sysmex HCV Test) Thermo Fisher Scientific (TaqMan HCV Test, HCV Viral Load Test) PerkinElmer (HCV Viral Load Test, HEV Serology Test) Qiagen (QIAstat-Dx Respiratory Panel, QIAamp Viral RNA Mini Kit) Becton, Dickinson and Company (BD) (BD MAX HCV Test, BD Veritor System forHCV) Myriad Genetics (Myriad RBM HCV Antibody Test, F. Hoffmann-La Roche LtD Hepatitis Testing Market Report Scope Report Attributes Details Market Size in 2023 US$ 3.53 billion Market Size by 2032 US$ 5.75 billion CAGR (2024–2032) 5.62% U.S. Market 2023 USD 1.22 billion U.S. Forecast by 2032 USD 1.94 billion Base Year 2023 Forecast Period 2024–2032 Key Regional Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Segment Analysis By Test: In 2023, the highest proportion of the diagnostic methods preferred for hepatitis detection was blood tests, which is primarily due to their non-invasive nature, high accuracy, and suitability for the detection of various hepatitis virus types (HBV, HCV, HAV, HEV). These tests are commonly used in hospitals and labs to screen for disease on a large scale. Imaging Studies Imaging procedures (primarily not used for diagnostic purposes) include ultrasound sonography and elastography, which are developing at a remarkable pace, especially in the context of the management of chronic viral hepatitis in the assessment of liver fibrosis. By Technology: ELISA technology dominated due to its dependable nature, cost-effectiveness, and production of high-throughput tests. It is a widely used method for the detection of hepatitis antigens and antibodies in all healthcare facilities. The PCR is more and more widely used as it is unequaled in sensitivity and accuracy, competing with viral RNA/DNA potentially at its early stage for a precise diagnosis and follow-up of patients. By End User: The Hospitals and Diagnostic Laboratories market is the largest revenue-generating testing location on account of a wider reach (hence greater accessibility), presence of high-end laboratory equipment for testing, and alignment with insurance-based payment models. The Home care segment is augmenting in the domestic hepatitis devices market as the preference for self-testing, home diagnostic kits, and remote care health monitoring grows among chronic hepatitis patients and the at-risk population. By Product: Reagents and Kits (60% contribution in 2023): Reagents and kits will continue to be at the centre-stage of hepatitis testing protocols, given their high utilization, the need for re-testing, and product advancements that increase test accuracy and reliability. Instruments: Increasing technology for automating tests, particularly in PCR and immunoassay systems, is a key growth driver for instruments in centralized and decentralized diagnostic locations. For a Personalized Briefing with Our Industry Analysts, Connect Now: Hepatitis Testing Market Segmentation By Test Blood tests Imaging tests Liver Biopsy By Technology Enzyme-linked immunosorbent assay (ELISA) Rapid Diagnostic Test Polymerase Chain Reaction (PCR) Isothermal Nucleic Acid Amplification Technology (INAAT) Others By End Use Hospitals & Diagnostic Labs Blood Banks Others By Product Instruments Reagents & Kits Regional Analysis In 2023, North America accounted for the largest share of the hepatitis testing market, with 43% of the global share, mainly due to high awareness levels, organized screening programs, and investments in the development of advanced diagnostic technologies. The APAC market is projected to witness the highest growth rate during the forecast period, due to the rising prevalence of hepatitis B and C, developed healthcare infrastructure, and favorable government policies in countries such as China, India, and Southeast Asia. Recent Developments In November 2023, F. Hoffmann-La Roche Ltd Two automated serology tests for hepatitis E diagnosis (Elecsys Anti-HEV IgM, IgG). These tests are among those on WHO's Essential Diagnostics List. In April 2024, BioMérieux unveiled a fully automated hepatitis B and C multiplex assay on its VIDAS platform, which is expected to offer a faster turnaround time in clinical labs. In March 2024, Abbott Laboratories designed an enhanced version of its RealTime HCV test on the m2000 platform to further increase sensitivity for low viral load the Full Hepatitis Testing Market Report (Single-User License) Now: Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 6. Competitive Landscape 7. Hepatitis Testing Market by Type 8. Hepatitis Testing Market by Technology 9. Hepatitis Testing Market by End Use 10. Hepatitis Testing Market by Product 11. Regional Analysis 12. Company Profiles 13. Use Cases and Best Practices 14. Conclusion About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@
Yahoo
26 minutes ago
- Yahoo
Christopher Brolly joins UBS as Financial Advisor in Boston
BOSTON, July 18, 2025--(BUSINESS WIRE)--UBS Global Wealth Management US announced that Christopher Brolly has joined the firm as a Financial Advisor. He joins the UBS Greater New England Market, led by Market Executive James Ducey, and will report to Boston Wealth Management Senior Market Director Robert Covino. "Christopher brings a wealth of experience and a devout commitment to client service with him to UBS," said Robert Covino. "We are confident that his expertise will greatly benefit our clients and contribute to our continued success here in the greater Boston market. We are excited to welcome him to our team." Christopher has over 15 years of experience providing advice and financial planning services for high and ultra-high net worth clients. He joins UBS from Morgan Stanley where he served as a Financial Advisor since 2012. Prior to that, he worked as a Financial Advisor at Merrill Lynch from 2008 to 2012, an Associate at Corwin & Corwin LLP from 2006 to 2008, and a Team Leader at Forrester Research from 1999 to 2002. Christopher holds a Juris Doctor from Boston University School of Law and a Bachelor of Arts from Syracuse University. Christopher is actively involved in his community in Marblehead, MA, where he has lived for the past 17 years. He is a dedicated member of Our Lady, Star of the Sea Parish and supports several parish initiatives, including the food pantry, clothing drive, and other philanthropic holiday programs. He is also a member of the Gerry 5 Veteran Fireman's Association and the Corinthian Yacht Club. Notes to Editors About UBSUBS is a leading and truly global wealth manager and the leading universal bank in Switzerland. It also provides diversified asset management solutions and focused investment banking capabilities. UBS manages 6.1 trillion dollars of invested assets as per fourth quarter 2024. UBS helps clients achieve their financial goals through personalized advice, solutions and products. Headquartered in Zurich, Switzerland, the firm is operating in more than 50 markets around the globe. UBS Group shares are listed on the SIX Swiss Exchange and the New York Stock Exchange (NYSE). © UBS 2025. All rights reserved. The key symbol and UBS are among the registered and unregistered trademarks of UBS. View source version on Contacts Media: Christina Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
